Abstract. The monocyte chemotactic protein 3 (MCP-3) belongs to the MCP subgroup of the CC chemokines and promotes chemotaxis of immune cells. MCP-1 is believed to play an important role in monocyte infiltration into tumor tissues; however, the relationship between tumor-infiltrating macrophage/microglia (TIM/M) and the expression of chemokines has not been investigated in detail in human glioma samples; therefore, we first examined the expression of several chemokines and chemokine receptors in human tumor cell lines, which included glioma lines, using real-time PCR. We found that several glioma lines expressed MCP-3 predominantly, and not MCP-1. In order to assess the significance of MCP-3 expression in human glioma tissues, we then examined the number of CD68 + TIM/M, the percentage of TIM/M in the total cell population, and the expression of MCP-1 and MCP-3 in glioma tissues. There was a correlation between the percentage of TIM/M and MCP-3 expression levels; however, there was no correlation between the percentage of TIM/M and MCP-1 expression. There was no correlation between the number of TIM/M and prognosis of patients. These data indicate that tumor cell-derived MCP-3, but not MCP-1, facilitates the infiltration of macrophage/ microglia into tumor tissues. This is the first study that clearly compared the significance of MCP-3 with that of MCP-1 in the tumor infiltration rates of TIM/M.
Introduction
Chemokines promote immune cell chemotaxis. Over 18 chemokines have been identified to date. Recently, a growing number of reports addressed the effect of chemokines on tumor environment and tried to assess whether chemokines promote or suppress tumor progression. Several CC chemokine gene transfer experiments have been performed, but a consensus has not yet been reached because of the multiple functions of chemokines. For example, monocyte chemotactic protein (MCP)-1, one of the best studied CC chemokines, has multiple functions and two-faced properties (1) (2) (3) (4) (5) (6) (7) . However, in the case of tumor-infiltrating macrophages (TIM), the abundant infiltration of TIM into tumor tissues is achieved via the action of MCP-1 (8) (9) (10) (11) , and TIM infiltration correlates with a worse disease prognosis in many cases (12) . In human gliomas, MCP-1 expression in the tumor tissue correlates with the recruitment of TIM/microglia (TIM/M) and has a poor disease prognosis (13) (14) (15) (16) . MCP-3 also belongs to the MCP subgroup of CC chemokines, which are structurally closely related but differ with respect to receptor usage; MCP-3 binds to the CCR1, CCR2, and CCR3 receptors, while MCP-1 binds exclusively to CCR2 (17) . MCP-3 and MCP-1 activate monocytes, T cells, eosinophils, and natural killer (NK) cells. In addition, MCP-3 activates dendritic cells (18) . Hence, the biological activities of MCP-1 and MCP-3 are thought to be distinct.
In comparison to MCP-1, it is unclear whether MCP-3 promotes tumor progression or not. However, there is evidence that MCP-3 might be a tumor suppressor. For instance, the transfection of MCP-3 into a rodent melanoma induced a type 1 T cell-dependent response, which resulted in the elimination of the melanoma (19) .
An effect (or lack thereof) of MCP-3 expression on the recruitment of TIM/M into human gliomas has not yet been reported. Therefore, in the present study, we focused on investigating the relationship between the expression of MCP-1 and MCP-3 chemokines and TIM/M infiltration into human gliomas. To this effect, we determined which chemokines and chemokine receptors were expressed in several human tumor cell lines, which led to the confirmation of the expression of MCP-1 and MCP-3 in glioma cell lines. We then analyzed the relationship between these chemokines and infiltration of TIM/M in surgically obtained human glioma paraffin-embedded specimens using immunohistochemistry. 
Materials and methods

Human
Polymerase chain reaction (PCR).
Total RNA was prepared using the TRIzol reagent (Invitrogen, Carlsbad, CA) and 600 ng were subjected to reverse transcription (RT) using Superscript III reverse transcriptase. Five microliters of 20x diluted cDNA samples, 1 μl each of forward and reverse primers (10 μM), 3 μl of PCR-grade water (Roche) and 10 μl of 2x concentrated SYBR green and Taq enzyme premixed reaction mixture (SYBR ® Premix Ex Taq™, Takara) were used for real-time PCR analysis. The sequences of the primer pairs used in this analysis are indicated in Table I . The reaction conditions consisted of one 5 min incubation at 95˚C followed by 45 cycles of 95˚C for 10 sec, 60˚C for 10 sec, and 72˚C for 10 sec, which were assessed by melting curve analysis. The reactions and analyses were performed on a LightCycler (Roche).
Human glioma samples. Surgically removed human glioma samples were fixed in 4% paraformaldehyde in phosphatebuffered saline (PBS) and were then embedded in paraffin. Sections (4 μm) were prepared and stained with hematoxylin and eosin (H&E) for pathological diagnosis. Paraffin blocks were used in accordance with the guidelines of the Ethics Table I . Primer pairs for real-time PCR analysis.
Forward primer sequence: F (5'→3') (Gene Bank accession no.)
Lower primer sequence: 
Committee of the Gifu University School of Medicine. Thirty-six cases of glioma were analyzed as described below.
Immunohistochemical analysis. Sections (4 μm) were prepared and specimens were deparaffinated and rehydrated. Each specimen was autoclaved in 10 mM citrate buffer pH 7.0 at 121˚C for 10 min, followed by washing with PBS. The specimens were stained with 10 μg/ml of mouse anti-human MCP-1 (clone 23002, mouse IgG2b, R&D System Inc.), mouse anti-human MCP-3 (clone polyclone, LifeSpan Biosciences), and mouse anti-human CD68 (clone KP-1, mouse IgG1κ, Dako) for 1 h at room temperature (RT) in a humidified chamber. After washing 3x10 min with PBS, the specimens were stained with Histofine Simple Stain MAX-PO(M) ® horseradish peroxidase-conjugated goat anti-mouse IgG (Nichirei Biosciences, Tokyo, Japan) for 1 h at RT. After washing 3x10 min with PBS, immunoreactions were visualized by incubation for 10 min in a solution containing 0.035% H 2 O 2 and 0.03% 3,3'-diaminobenzidine (Wako, Tokyo, Japan) in 50 mM Tris-HCl (pH 7.6). Sections were fixed in 4% paraformaldehyde for 10 min and were then counterstained with H&E and submitted for observation.
Analysis of stained sections. We observed each specimen at magnification x400 using a 10-mm square (1 mm divisions) micrometer (Olympus, Tokyo, Japan); thus, each observation represented an actual area of 0.25x0.25 mm. We counted at least 400 hematoxylin-positive cells as the total number of the cells, and the number of CD68 + cells was counted simultaneously in the same field.
Statistical analysis. We used the Mann-Whitney U test for single parameter comparisons. We used regression analysis to assess the correlation between two parameters. Probability values <0.05 were considered significant.
Results
MCP-1 and MCP-3 were highly expressed in tumor cell lines when compared with other chemokines.
We examined the expression levels of chemokines and chemokine receptors in a variety of human tumor cell lines (Fig. 1) . The expression levels of CCL3 and CCL4 were very low in the lines examined, with the exception of HeLa cells. In addition, MCP-1 expression was observed in 2 out of 5 non-glioma tumors, and in 4 out of 5 glioma tumors. Non-glioma tumor cell lines all expressed MCP-3 and 2 out of 5 glioma tumors expressed this chemokine; however, the expression levels of MCP-3 in glioma cases were much higher than those observed for MCP-1 in all glioma cases. The MCP-1 and MCP-3 common receptors were not expressed in any of the tumors analyzed, with the exception of the low expression of CXCR4 on A172 and SNB19. These data indicate that, similarly to that observed for MCP-1, MCP-3 could be a candidate molecule secreted by tumor cells and involved in the chemotaxis of monocytes to tumor sites. The high expression of MCP-3 suggests that this molecule may be a predominant factor affecting the infiltration of monocytes into tumor sites.
Percentage of TIM/M in human glioma tissue samples correlated with WHO grade of the tumors.
Because the density of TIM is generally correlated with a worse disease prognosis (12), we examined the number of TIM/M in surgically removed human glioma tumor tissue samples using CD68 staining, as CD68 is a marker of macrophages (20) and microglia (21) . The clinicopathological data of all cases are summarized in Table II . As shown in Fig. 2 , the percentage of TIM/M versus the total number of cells in the tumor tissue seemed to increase with increasing WHO grade of the glioma.
The infiltration of TIM/M in human gliomas correlated with MCP-3 expression patterns, but not with those of MCP-1.
Next, we examined the expression of MCP-1 and MCP-3 and calculated the number of TIM/M in tumor tissue samples. The representative staining patterns of MCP-1, MCP-3, and CD68 are shown in Fig. 3 (case nos. 7 and 32 ). MCP-1 and MCP-3 staining was preferentially detected in cells exhibiting nuclear atypia or in large cells (rather than in mononuclear cells). This indicated that MCP-1 and MCP-3 were predominantly expressed in tumor cells; therefore, we classified tumors into MCP-1-or MCP-3-positive and -negative status: the immunohistochemical analysis results for each specimen are summarized in Table III . As shown in Fig. 4A , there were no significant differences in CD68 staining between MCP-1-negative and -positive cases (P=0.1404). In contrast, there Table II . Clinical data for the 36 glioma cases. was a significant difference in CD68 staining between MCP-3-negative and-positive cases (P<0.001) (Fig. 4B) . Furthermore, the classification of the tumors into four groups based on the staining pattern of MCP-1 and MCP-3 revealed that MCP-3-positive cases had a significantly higher level of infiltration of macrophages/microglia. These data clearly indicate that, of the two chemokines studied here, MCP-3 is the predominant factor for macrophage/microglia infiltration into tumor tissues.
-------------------------------------------------
-------------------------------------------------
Discussion
In the present study, we focused on the involvement of MCP-3 expression in the infiltration of macrophages/microglia into tumor tissues. The expression level of the MCP-3 mRNA in glioma cell lines was higher than that of MCP-1 (Fig. 1B) . Moreover, we showed that the percentage of TIM/M was Table III . Summary of immunohistochemical staining of the 36 specimens. were activated to cleave both chemokines, this would result in the inactivation of both chemokines. Furthermore, if MMP-2, 13, or 14 were activated to cleave MCP-3, the truncated MCP-3 would also interfere with MCP-1 function as truncated MCP-3 binds to all its receptors including the MCP-1 receptor CCR2. However, our results clearly showed a specific correlation between MCP-3 expression (but not MCP-1 expression) and the infiltration of TIM/M. Therefore, MMPs would not appear to be strongly involved in the regulation of MCP-1 and MCP-3 cleavage in our study. Second, the differences in receptor usage between MCP-1 and MCP-3 suggest another possibility. As mentioned in the Introduction, MCP-1 binds to CCR2 exclusively, whereas MCP-3 binds to CCR1, CCR2, and CCR3 (17) . Human CD14 + monocytes express both CCR1 and CCR2 (28) . This implies that MCP-3, but not MCP-1, can activate both receptors in monocytes. In addition, an MCP-1 knockout mouse does not exhibit diminished infiltration of macrophages (29) . These reports suggest that MCP-3 is more important in monocyte recruitment into peripheral tissues than MCP-1. As shown in Fig. 2 , immunohistochemical staining for CD68 in human glioma specimens revealed that the percentage of TIM/M significantly increased with the increasing WHO grade of glioma (Fig. 2) ; however, we did not find a correlation between the percentage of TIM/M and disease prognosis (data not shown), in agreement with what was reported by Yao et al (30) . Regarding the absence of a correlation between CD68 + TIM/M infiltration and patient prognosis, we should consider the status of TIM/M activation as several different classifications have been proposed for monocyte/macrophage activation (31, 32) , and tumor-infiltrating macrophages are preferentially activated toward alternatively activated phenotypes (33) . The scavenger receptor CD136 and the mannose receptor CD204 are markers of the alternatively activated phenotype of TIM/M. Interestingly, a recent study mentioned the effect of the expression of CD136 and CD204 in TIM/M on the prognosis of glioma patients (34) . Although we showed tumor cell-derived MCP-3 played a predominant role in the recruitment of macrophage/microglia into tumor tissues, the infiltration was not sufficient for the maintencance of the immunosuppressive property of the TIM/M; rather activation/maturation towards alternatively activated phenotype was the important factor. As described above, MCP-3 acts not only on monocytes but also on several types of leukocytes (18) ; therefore, neither the neutralization nor the blocking of MCP-3 can be used to prevent monocyte/macrophage infiltration. Instead, the prevention of macrophage activation toward an alternatively activated phenotype should be considerd to be the target of choice for immunotherapy of cancer patients.
In conclusion, we showed the significance of MCP-3 for infiltration of TIM/M into human glioma tissue samples. This is the first report on human glioma samples to show the significance of glioma cell-derived MCP-3 for the recruitment of TIM/M.
